---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-26-000028"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:46:52.041115+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Praxis reports Q4 net loss $88.9M; submits two NDAs; cash $926M

## Summary
- Net loss $88.9M in Q4 2025 ($303.3M FY), vs $58.7M ($182.8M FY) prior year.
- Cash and investments $926.1M at Dec 31, 2025; plus $621.2M Jan 2026 offering funds operations into 2028.
- Submitted NDAs to FDA for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs).
- Topline results expected H1 2026 for vormatrigine Phase 3 (POWER1) and elsunersen EMBRAVE Part A.
- Board additions: Jeffrey Kindler, Stuart Arbuckle; promoted Sniecinski to COO, Petrou to President R&D.

## SEC filing metadata
- accession: 0001689548-26-000028
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/0001689548-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/prax-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-26-000028
- JSON: https://secwatch.observer/filing/0001689548-26-000028.json
- Plain text: https://secwatch.observer/filing/0001689548-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.